Skip to search formSkip to main contentSkip to account menu

FOLFOX Regimen

Known as: CF/5-FU/L-OHP, FOLFOX, Fluorouracil/Leucovorin Calcium/Oxaliplatin 
An abbreviation for a chemotherapy combination used to treat colorectal cancer that is advanced or has come back. It is also being studied in the… 
National Institutes of Health

Related topics

Related topics

4 relations
FluorouracilFolfox protocolLeucovorin Calciumoxaliplatin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial
Importance KRAS mutations are common in pancreatic cancer, but directly targeting the KRAS protein has thus far been unsuccessful… 
Highly Cited
2017
Highly Cited
2017
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade.
In a patient with colon cancer and a history of autoimmunity, skin and gastrointestinal toxicity developed after the receipt of… 
Highly Cited
2016
Highly Cited
2016
Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens
Evidence suggests that lean body mass (LBM) may be useful to normalize chemotherapy doses. Data from one prospective and one… 
Highly Cited
2014
Highly Cited
2014
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label…
Review
2014
Review
2014
Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer.
Standard therapy for locally advanced rectal cancer (LARC) is preoperative chemoradiotherapy and postoperative chemotherapy. At… 
Highly Cited
2014
Highly Cited
2014
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt…
LBA3 Background: Irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6), combined with bevacizumab (BV… 
Highly Cited
2010
Highly Cited
2010
Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases
BackgroundThe optimal duration, safety, and benefit of preoperative chemotherapy in patients with colorectal liver metastases… 
Highly Cited
2009
Highly Cited
2009
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
PURPOSE This study compared chemotherapy discontinuation with maintenance therapy with leucovorin and fluorouracil after six… 
Highly Cited
2009
Highly Cited
2009
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Highly Cited
2007
Highly Cited
2007
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.
PURPOSE Liver metastases represent the principal cause of death in patients with advanced colorectal cancer (CRC). Injection of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)